Sign up Australia
Proactive Investors - Run By Investors For Investors

Race Oncology reveals promising results for its chemotherapy drug

Two girls in France have had a successful response to the treatment with Bisantrene.
cancer cells
Granted an Orphan Drug Designation in the US

Race Oncology Ltd (ASX:RAC) has revealed a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia).

Bisantrene is a small-molecule chemotherapy drug related to anthracyclines, the most frequently prescribed type of cancer drug and first line of treatment for many cancers.

Race owns two patents on Bisantrene, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML.

Two girls in France fully respond to treatment

The case report describes two girls in France who were successfully treated with Bisantrene in 1984 and 1991. Both remain alive today.

Race chief executive officer Peter Molloy explained: “One of the girls was seven years old when diagnosed with AML in 1984”

“She had relapsed after multiple lines of standard chemotherapy and was treated with one 7-day course of Bisantrene, followed by other chemotherapy.

“She had a complete response to the treatment, which allowed her to receive a bone marrow transplant. As a result, she’s alive today and the mother of three children.”

WATCH: Race Oncology director sees "extreme, untapped value" in company's cancer drug

The other girl was 13 years old when diagnosed in 1990 and also had relapsed after multiple lines of standard chemotherapy.

In 1991, she received Bisantrene treatment in combination with two standard chemotherapy agents.

Molloy added: “She also had a complete response, which allowed her to receive a bone marrow graft. Thankfully, she is still alive today and has a three-year old child.”

View full RAC profile View Profile

Race Oncology Ltd Timeline

Newswire
February 15 2017

Related Articles

Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use